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Abstract 
Introduction:Hemophagocytosis Lymphohistiocytosis (HLH) is a syndrome of inappropriate 
hyperimmune response.  
Presentation of Case:We present a case of secondary HLH associated with systemic lupus 
erythematous (SLE) and liver dysfunction. 
Conclusion:This case report focuses on the diagnostic dilemmas with HLH and an 
individualized treatment approach to the patient. 
 
 
 
 
 
 
  
 
Kumar Ret al.American Journal of Cancer Case Reports 2018, 6:46-51                                                                          Page 2 of 6 
Ivy Union Publishing | http: //www.ivyunion.org                                   December 29, 2018 | Volume 6, Issue 1 
 
Introduction 
Hemophagocytosis Lymphohistiocytosis (HLH) is a syndrome of inappropriate hyperimmune 
response[1].It has been described as Primary or Familial (due to gene mutation) or Secondary HLH 
(due to a specific trigger e.g. malignancy – 38%, infection – 32%, autoimmune disease – 12%)[2]. 
HLH associated with rheumatologic diseases is termed as macrophage activation syndrome (MAS)[3]. 
The excessive tissue inflammation and organ dysfunction in HLH is due to dysregulation of cytotoxic 
T-cells, Natural killer (NK) cells and macrophages with associated increased secretion of 
cytokines[3].Due to rarity of this syndrome, no clear guidelines for its management have been 
established, especially in adult population. Most of our current knowledge has been based on studies 
done in children. Here we present a case of secondary HLH associated with systemic lupus 
erythematous (SLE) in an adult – the diagnostic dilemma it posed and an individualized treatment 
approach to the patient. 
Case Description 
A 24-year-old Hispanic female with history of recently diagnosed systemic lupus erythematous (SLE) 
presented to our hospital with fever, abdominal pain with nausea and vomiting worsening for 2 months. 
She was evaluated at an outside clinic 4 weeks ago for similar presentation and was diagnosed with 
SLE. Patient refused medical treatment and opted for herbal therapy at that time. There was no 
significant family history. On presentation she was febrile to 102F but hemodynamically stable. 
Physical examination was remarkable for erythematous indurated plaqueson face and bilateral hands, 
oral ulcers and RUQ abdominal tenderness. No organomeglyor lymphadenopathy was palpated. Initial 
diagnostic work-up was remarkable for deranged liver enzymes (ALP 166U/L, GGT 157U/L, AST 
199U/L and ALT 189U/L), LDH 535U/L, ANA+ >1:160 (speckled), DS- DNA 57IU/ml (Normal 0-
4IU/ml), low complements and elevated ESR. The hemoglobin (Hb) was 10.8g/dL,white cell count 
2.8k/µL and platelet count 69k/µL. She was found to have ferritin of 7123ng/ml. Extensive infectious 
work up (bacterial, viral and fungal) and toxicology screen was negative. Computed tomography (CT) 
scans revealed hepatomegaly, bilateral axillary, mediastinal and right hilar lymphadenopathy (LAD). 
Spleen size was normal. A presumptive diagnosis of secondary HLH or MAS associated with SLE was 
made. She had skin, liver, axillary LAD and bone marrow biopsy with no malignancy on pathology. 
Bone marrow biopsy revealednormocellular marrow with no atypical cells. She received empiric 
broad-spectrum antimicrobial therapy initially but was discontinued due to no improvement in clinical 
condition. She also received pulse steroid therapy but her symptoms and laboratory parameters 
deteriorated significantly (Table 1). Magnetic resonance imaging (MRI) was unremarkable for 
obstructive etiology of worsening liver functions. Natural Killer (NK) cell activity came back low and 
she met the HLH-2004 diagnostic criteria.She was started on HLH-94 treatment protocol(Etoposide 
and dexamethasone). Given her clinical condition and severely deranged liver function she was started 
on very low dose of Etoposide (30mg/m2). The dose was escalated as both clinical and laboratory 
parameters improved (Table 2). After 2 cycles of chemotherapy, she developed altered mental status 
and was intubated for airway protection. She was worked up for CNS involvement of HLH. The 
cerebrospinal fluid analysis, MRI brain and electroencephalogramwere normal. She received weekly 
intrathecal Methotrexate and hydrocortisone for presumed HLH-CNS involvement. She improved 
  
 
Kumar Ret al.American Journal of Cancer Case Reports 2018, 6:46-51                                                                          Page 3 of 6 
Ivy Union Publishing | http: //www.ivyunion.org                                   December 29, 2018 | Volume 6, Issue 1 
 
significantly and was discharged to complete chemotherapy as outpatient. After completion of 8 cycles 
of chemotherapy her symptoms were resolved and there was significant downtrend in laboratory 
parameters (Table 1 and Fig 1). She continued to have close outpatient follow up to monitor for HLH 
relapse.She was started on azathioprine, Plaquenil and prednisone for SLE treatment. 
 
Table 1Trend of Laboratory Parameters 
Laboratory parameters At presentation Peak/nadir values  
(before chemotherapy) 
After chemotherapy  
completion 
 
Albumin (g/dL) 
Bilirubin (Total/direct) (mg/dL) 
ALP/GGT/AST/ALT (U/L) 
LDH (U/L) 
Ferritin (ng/ml) 
PT/PTT (seconds) 
Fibrinogen (mg/dL) 
Triglyceride (mg/dL) 
Serum creatinine (mg/dL) 
Creatinine Clearance (ml/min) 
 
3.4 
0.4/0.3 
166/157/199/189 
535 
7123 
13.1/53 
575 
133 
0.4 
185 
 
2 
10.6/6.6 
1308/1589/1716/1308 
2124 
37, 632 
12.5/34.1 
422 
408 
0.4 
185 
 
4.2 
0.2/0.1 
122/156/32/27 
183 
400 
11.4/24.5 
499 
123 
0.4 
185 
 
Table 2 Modified HLH-94 Regimen 
Cycle Chemotherapy 
C1 1. Etoposide 30mg/m2+ Dexamethasone 10mg/m2 
2. Etoposide 30mg/m2+ Dexamethasone 10mg/m2 
C2 1. Etoposide 45 mg/m2+ Dexamethasone 10mg/m2 
2. Etoposide 75 mg/m2+ Dexamethasone 10mg/m2 
C3 1. Etoposide 112.5 mg/m2+ Dexamethasone 5mg/m2 
C4 1. Etoposide 150 mg/m2+ Dexamethasone 5mg/m2 
C5 1. Etoposide 150 mg/m2+ Dexamethasone 2.5mg/m2 
C6 1. Etoposide 150 mg/m2+ Dexamethasone 2.5mg/m2 
C7 1. Etoposide 150 mg/m2+ Dexamethasone 1.25mg/m2 
C8 1. Etoposide 150 mg/m2+ Dexamethasone tapered to zero 
 
Discussion 
The diagnosis of HLH is established by either molecular diagnosis consistent with HLH or fulfillment 
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of 5 out of 8 following criterion – Fever, splenomegaly, cytopenia• 2-3 lineages in peripheral blood  
(Hb<9g/dL, Platelets <100k/µL, neutrophils < 100/µL), hypertriglyceridemia (>265mg/dL) and/or 
hypofibrinogenemia (<1.5g/L), hemophagocytosis in bone marrow, spleen or lymph nodes, low or 
absent NK cell activity, ferritin • 500 µg/L or soluble CD25 (sIL2r) • 2400U/mL [4].Of note, this 
diagnostic criterion has not been validated in adult population that has predominantly secondary HLH. 
A diagnostic score to estimate risk of secondary HLH, the HScore, is freely available at 
saintantoine.aphp.fr/score (90% in our patient)[5]. More so, some authors have suggested MAS 
specific diagnostic criterion[6, 7].The distinction of primary versus secondary HLH is not needed for 
management of acute phase but may be required to plan long-term treatment strategy[1].Due to lack of 
standardized diagnostic approach, we recommend clinician to be aware of the causes of secondary 
HLH and have high clinical suspicion if above suggestive features are present because untreated HLH 
has high fatality rate. Other associated findings are hepatomegaly, hyperbilirubinemia, transaminitis, 
elevated LDH, CNS involvement (may have pleocytosis and/or elevated protein on CSF analysis) or 
skin manifestations[8].Our patient met the diagnostic criteria for HLH, although no hemophagocytosis 
was seen on multiple biopsies, which is neither sensitive nor specific for HLH due to sampling error 
and its manifestations later in disease course[9, 10].  
 The mainstay of HLH therapy is based on Etoposide and dexamethasone from HLH-94 
treatment protocol. The regimen includes etoposide 150mg/m2 (twice weekly for 2 weeks then weekly 
for 6weeks) and tapered dose of dexamethasone (weeks 1 and 2 – 10mg/m2, weeks 3 and 4 – 5mg/m2, 
weeks 5 and 6 -2.5mg/m2, week 7 – 1.25mg/m2 and week 8 – taper dose to zero)[11]. The final results 
of HLH-2004 study, that included cyclosporine in the initial treatment, are still awaited. Hematopoietic 
Stem Cell Therapy (HSCT) may be considered in primary HLH or patients who have disease relapse 
or refractory to HLH-specific therapy. Although better long-term cure has been achieved with HSCT 
in children age <16, it should be considered on case-by-case basis in adult population due to lack of 
good supportive evidence[1, 12]. In CNS involvement, weekly intrathecal hydrocortisone and 
methotrexate is standard of care. Every effort should be made to identify the triggering factor in 
secondary HLH because in a stable patient controlling the trigger itself may halt the excessive immune 
response negating the need for more toxic HLH specific therapy[1, 10]. In MAS, treatment of the 
rheumatologic disorder with pulse steroids +/- cyclosporine is the mainstay therapy but some patient 
may require addition of etoposide[3, 10]. In unstable patient, HLH-specific therapy should not be 
withheld while attempting to identify or control the trigger due to high mortality associated with HLH. 
Our patient’s both clinical and laboratory parameters severely worsened even after she received a 
course pulse steroid. This led to the decision of treating her with HLH-specific therapy.  
 The main component of the therapy, Etoposide, is metabolized in the liver and renally 
excreted. A dose reduction of 25-75% is recommended based on the creatinine clearance but the dose 
adjustment in hepatic dysfunction is less clear[8].While some authors do not recommend dose 
reduction in isolated hyperbilirubinemia but in severe hepatic dysfunction, as in this patient, a dose 
escalation of etoposide may be considered as the liver function improves. An important point to be 
mentioned here is that the recommended dose of etoposide, 150mg/m2, is based on the study done in 
children that may be unnecessary and more toxic in adults. A maximum dose of 100mg/m2 etoposide 
has been suggested to minimize myelosuppression and predisposition to infection[1].Our patient 
received a starting dose of 30mg/m2 and with improvement in liver function, she was able to tolerate 
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full dose of 150mg/m2. Alemtuzumab may be a reasonable alternative to Etoposide in patients with 
severe hepatic dysfunction[13]. 
 The response to therapy may be monitored by the trend of ferritin levels. Although sIL-
2r(soluble IL-2 receptor) and sCD163 (a receptor for hemoglobin-haptoglobin complexes) levels are 
better markers of disease activity, these tests are expensive and not readily available[14].Our patient 
had a very good response to Etoposide dose escalation therapy with significant downtrend in ferritin, 
bilirubin and liver enzymes. 
 The treatment recommendations based on HLH-94 study may not be fully applicable to adult 
population. In the face of paucity of data, we recommend an individualized treatment approach to 
HLH in adult patients.   
 
 
Learning points: 
• Secondary HLH is commonly associated with malignancy, infection or autoimmune disease. 
• Treating the triggering factor in secondary HLH, especially MAS may negate the need for 
more toxic HLH-specific therapy. 
• A minority of patients with MAS may require etoposide in addition to steroids. 
• Most of the HLH recommendations are based on studies done in children and a more 
individualized treatment approach should be opted in adult patients. 
 
 
Fig. 1Trend of Ferritin Levels 
 
 
0
5000
10000
15000
20000
25000
30000
35000
40000
1 2 3 4 5 6 7 8
Ferritin (ng/ml)
Fe
rr
iti
n 
(n
g/
m
l)
Chemotherapy Cycle
  
 
Kumar Ret al.American Journal of Cancer Case Reports 2018, 6:46-51                                                                          Page 6 of 6 
Ivy Union Publishing | http: //www.ivyunion.org                                   December 29, 2018 | Volume 6, Issue 1 
 
References 
1. La Rosee P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc 
Hematol Educ Program. 2015, 2015:190-196 
2. Birndt S, Schenk T, Brunkhorst FM, Maschmeyer G, Rothmann F, Weber T, Müller M, Panse JP, 
Schroers R, Braess J, Frickhofen N, Janka G, Lehmberg K, Hochhaus A, Ernst T, La Rosée P. 
Hemophagocytic lymphohistiocytosis in adults (ahlh): Results from the german hlh registry. 
Blood. 2016, 128:2523-2523 
3. Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best 
Pract Res Clin Rheumatol. 2014, 28:277-292 
4. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, 
Webb D, Winiarski J, Janka G. Hlh-2004: Diagnostic and therapeutic guidelines for 
hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48:124-131 
5. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. 
Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic 
syndrome. Arthritis Rheumatol. 2014, 66:2613-2620 
6. Ravelli A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin 
Exp Rheumatol. 2004, 22:271-275 
7. Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, Cron RQ, Ravelli A, Group 
MASS. An international consensus survey of diagnostic criteria for macrophage activation 
syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011, 38:764-768 
8. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How i treat hemophagocytic 
lymphohistiocytosis. Blood. 2011, 118:4041-4052 
9. Kleynberg RL, Schiller GJ. Secondary hemophagocytic lymphohistiocytosis in adults: An update 
on diagnosis and therapy. Clin Adv Hematol Oncol. 2012, 10:726-732 
10. Weitzman S. Approach to hemophagocytic syndromes. Hematology Am Soc Hematol Educ 
Program. 2011, 2011:178-183 
11. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, 
Imashuku S, Komp D, Ladisch S, Webb D, Janka G, Histocyte S. Treatment of hemophagocytic 
lymphohistiocytosis with hlh-94 immunochemotherapy and bone marrow transplantation. Blood. 
2002, 100:2367-2373 
12. Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch S, 
Webb D, Janka G, Henter JI, Histiocyte S. Chemoimmunotherapy for hemophagocytic 
lymphohistiocytosis: Long-term results of the hlh-94 treatment protocol. Blood. 2011, 118:4577-
4584 
13. Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, Lee ND, Khan SP, Lawrence 
J, Mo JQ, Bleesing JJ, Filipovich AH, Jordan MB. Salvage therapy of refractory hemophagocytic 
lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013, 60:101-109 
14. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, 
Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA. The diagnostic 
significance of soluble cd163 and soluble interleukin-2 receptor alpha-chain in macrophage 
activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis 
Rheum. 2007, 56:965-971 
 
 
